Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are to assess whether 80 mg ixekizumab every 2-week (Q2W) is: 1. noninferior to ustekinumab at Week 12 in the treatment of patients with moderate to severe psoriasis, as measured by proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90, and then 2. superior to ustekinumab at Week 12 in the treatment of patients with moderate-to-severe plaque psoriasis, as measured by proportion of patients achieving PASI 90
Critère d'inclusion
- Moderate to Severe Plaque Psoriasis